Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib with or without anti-VEGF in advanced renal cell carcinoma
NCT01664182Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Dec 2020
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of trebananib in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Aug 2012; status: completed.
02
Drugs
trebananib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01664182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01664182.